[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-339308-105":59,"doc-detail-339308-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","clinical-and-biologic-correlates-of-adora2a-transcriptomic-expression-in-cancer","Clinical and Biologic Correlates of ADORA2A Transcriptomic Expression in Cancer","","ADORA2A (adenosine A2a receptor) and ADORA2B transmit immunoregulatory signals, including limiting innate and adaptive immunity, with emerging evidence of tumor suppressor roles in specific contexts. RNA expression was assessed across 514 tumors, with 489 advanced/metastatic patients linked to clinical outcomes. Transcript levels were standardized and ranked on a 0–100 scale against 735 specimens from 35 cancer types, defining low/moderate (0–74) and high (75–100) ADORA2A expression. High ADORA2A occurred in 20.8% of tumors, showing cancer-type differences and associations with immune checkpoint molecules, and demonstrated favorable prognostic value unrelated to immunotherapy.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/clinical-and-biologic-correlates-of-adora2a-transcriptomic-expression-in-cancer/339308/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/clinical-and-biologic-correlates-of-adora2a-transcriptomic-expression-in-cancer/339308.png","ImageObject",300,407,{"name":92,"@type":93},"Aurora","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is ADORA2A and why is it important in cancer?","Question",{"text":112,"@type":113},"ADORA2A is an adenosine A2a receptor (a GPCR) involved in immunoregulatory signaling. It influences tumor-immune interactions through pathways that affect immune cell function and adenosine-driven checkpoint effects.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was ADORA2A transcript expression measured and categorized?",{"text":117,"@type":113},"RNA expression was evaluated in tumors using standardized internal housekeeping genes and a ranked 0–100 percentile scale. Expression was classified as low/moderate (0–74) or high (75–100) based on percentile RNA ranks.",{"name":119,"@type":110,"acceptedAnswer":120},"What clinical correlations were observed with high ADORA2A?",{"text":121,"@type":113},"High ADORA2A was associated with higher expression of immune checkpoint-related molecules such as PD-1, VISTA, CD38, and CD39. In immunotherapy-treated patients, high ADORA2A did not significantly correlate with progression-free or overall survival, but it correlated with longer overall survival from advanced/metastatic disease onset.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},339308,1791131566,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},4810365810221,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Article  \nClinical and Biologic Correlates of ADORA2A Transcriptomic Expression in Cancer  \nAditya Shreenivas 1, *,†, Daisuke Nishizaki 2,†, Suzanna Lee 2, Sarabjot Pabla 3, Mary Nesline 3, Jeffrey M. Conroy 3, Paul DePietro 3, Shumei Kato 2,‡ and Razelle Kurzrock 1,4,5, *,‡  \nCitation: Shreenivas, A.;  \nNishizaki, D.; Lee, S.; Pabla, S.;  \nNesline, M.; Conroy, J.M.; DePietro, P.; Kato, S.; Kurzrock, R. Clinical and Biologic Correlates of ADORA2A Transcriptomic Expression in Cancer. Int. J. Mol. Sci. 2024, 25, 4742 . [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)ijms25094742  \nAcademic Editor: Anne Vejux  \nReceived: 23 March 2024  \nRevised: 18 April 2024  \nAccepted: 22 April 2024  \nPublished: 26 April 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Department of Oncology, Medical College of Wisconsin Cancer Center, Milwaukee, WI 53226, USA  \n2 Center for Personalized Cancer Therapy and Division of Hematology and Oncology, Department of Medicine, UC San Diego Moores Cancer Center, La Jolla, CA 92037, USA  \n3 Labcorp Oncology, Buffalo, NY 14203, USA  \n4 WIN Consortium, 24, rue Albert Thuret, 94550 Chevilly-Larue, France  \n5 Department of Medical Oncology, University of Nebraska, Omaha, NE 68105, USA  \n* Correspondence: [ashreenivas@mcw.edu](ashreenivas@mcw.edu) (A.S.); [rkurzrock@mcw.edu](rkurzrock@mcw.edu) (R.K.)† These authors contributed equally to this work.  \n‡ These authors contributed equally to this work.  \nAbstract: ADORA2A (adenosine A2a receptor) and ADORA2B propagate immunoregulatory signals, including restricting both innate and adaptive immunity, though recent data also suggest a tumor suppressor effect in certain settings. We evaluated the RNA expression from 514 tumors in a clinicalgrade laboratory; 489 patients with advanced/metastatic disease had clinical outcome correlates. Transcript expression was standardized to internal housekeeping genes and ranked (0–100 scale) relative to 735 specimens from 35 different cancer types. Transcript abundance rank values were defined as “low/moderate”(0–74) or “high”(75–100) percentile RNA expression ranks. Overall, 20.8% of tumors had high ADORA2A (≥75 percentile RNA rank) . The greatest proportion of high ADORA2A expressors was found in neuroendocrine and breast cancers and sarcomas, whereas the lowest was found in colorectal and ovarian cancers, albeit with patient-to-patient variability. In multivariable logistic regression analysis, there was a significant positive correlation between high ADORA2A RNA expression and a high expression of the immune checkpoint-related molecules PD-1 (p = 0.015), VISTA (p ≤ 0.001), CD38 (p = 0.031), and CD39 (p ≤ 0.001) . In 217 immunotherapy-treated patients, high ADORA2A did not correlate significantly with progression-free (p = 0.51) or overall survival (OS) (p = 0.09) from the initiation of the checkpoint blockade. However, high versus not-high ADORA2A transcript expression correlated with longer OS from the time of advanced/metastatic disease (N = 489 patients; (HR 0.69 (95% CI 0.51–0.95) (p = 0.02)) . Therefore, high ADORA2A transcript levels may be a favorable prognostic factor, unrelated to immunotherapy. Importantly, ascertaining co-expression patterns of ADORA2A with PD-1 and VISTA in individual tumors asa basis for the precision co-targeting of ADORA2A and these other checkpoint-related molecules warrants investigation in clinical trials.  \nKeywords: ADORA2A; immune checkpoints; adenosine pathway  \n1. Introduction  \nThe adenosine A2a receptor (ADORA2A) is a member of the guanine nucleotidebinding protein (G protein)-coupled receptor (GPCR) superfamily [1] . ADORA2A and ADORA2B ar","cbCaiaBlsA7AkbZx","https://ap.wps.com/l/cbCaiaBlsA7AkbZx","pdf",1855148,13,"English","# Abstract\n# Introduction","[{\"question\":\"What is ADORA2A and why is it important in cancer?\",\"answer\":\"ADORA2A is an adenosine A2a receptor (a GPCR) involved in immunoregulatory signaling. It influences tumor-immune interactions through pathways that affect immune cell function and adenosine-driven checkpoint effects.\"},{\"question\":\"How was ADORA2A transcript expression measured and categorized?\",\"answer\":\"RNA expression was evaluated in tumors using standardized internal housekeeping genes and a ranked 0–100 percentile scale. Expression was classified as low/moderate (0–74) or high (75–100) based on percentile RNA ranks.\"},{\"question\":\"What clinical correlations were observed with high ADORA2A?\",\"answer\":\"High ADORA2A was associated with higher expression of immune checkpoint-related molecules such as PD-1, VISTA, CD38, and CD39. In immunotherapy-treated patients, high ADORA2A did not significantly correlate with progression-free or overall survival, but it correlated with longer overall survival from advanced/metastatic disease onset.\"}]","Clinical and Biologic Correlates of ADORA2A Transcriptomic Expression in Cancer | PDF",1790029384,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/93cd247328ea91e9c30c4d51ec78e0b8.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9f539ac8e613d14cf82c3f2b4f3f4329.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/96e0350fc11a76f38b3e946a42163903.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/687889a412eaf9356484920651004865.webp",980,1385]